Click a link below to view the mailing archive as if it had been sent to you.
| 2022-12-30 12:15 | | Biogen, FDA's inappropriate Aduhelm coordination detailed in blistering congressional report and more... |
| 2022-12-29 00:15 | | UCB's bimekizumab finally back on the FDA's review list after May rejection and more... |
| 2022-12-23 12:15 | | BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165 and more... |
| 2022-12-22 12:15 | | Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say and more... |
| 2022-12-22 00:15 | | Zynerba cites 'tripledemic' for PhIII delay of a cannabinoid drug that's failed multiple times and more... |
| 2022-12-21 12:15 | | Ahead of lecanemab decision, Alzheimer's groups petition CMS to reverse coverage policy and more... |
| 2022-12-21 00:15 | | Biopharma Executive Perspectives on 2023 and more... |
| 2022-12-20 12:15 | | Kite swoops in to buy Carl June-founded Tmunity, gaining key to Penn's CAR-T research apparatus and more... |
| 2022-12-20 00:15 | | Novartis to cut 280+ jobs in New Jersey and more... |
| 2022-12-19 12:15 | | Here Are the Top Five Biotech Trends for 2023 and more... |
| 2022-12-16 12:15 | | AZ wins patent fight with Viatris, gains more exclusivity for blockbuster Symbicort and more... |
| 2022-12-16 00:15 | | AbbVie leaves PhRMA, BIO: reports and more... |
| 2022-12-15 12:15 | | Axcella axes NASH program, 85% of staff in last-ditch focus on long COVID and more... |
| 2022-12-15 00:15 | | Novartis sells U.S. rights to five drugs to Harrow for up to $175M and more... |
| 2022-12-14 12:15 | | Biopharma’s 5 Biggest M&A Deals of 2022 and more... |
| 2022-12-14 00:15 | | Pfizer projects mRNA vaccine sales will hover around $15B by 2030 and more... |
| 2022-12-13 12:15 | | Takeda wagers up to $6B on Nimbus’ TYK2 drug and more... |
| 2022-12-13 00:15 | | ASH: Bristol's 3rd-line Abecma data didn't make the trip to New Orleans. Is it cause for concern? and more... |
| 2022-12-12 12:15 | | Amgen to Buy Horizon in Biotech’s Biggest Deal of 2022 and more... |
| 2022-12-12 00:15 | | ASH: Despite partial clinical hold, bluebird's sickle cell gene therapy remains on track and more... |
| 2022-12-09 12:15 | | SABCS: AZ writes the 'next chapter' in Enhertu's saga with head-to-head win versus Roche's Kadcyla and more... |
| 2022-12-09 00:15 | | Jynneos mpox vaccine provided strong protection against infection, new CDC data show and more... |
| 2022-12-08 12:15 | | Life sciences M&A values halve, volumes plunge. Will we ever see deals pick up again? and more... |
| 2022-12-08 00:15 | | Pfizer's RSV vaccine rush gets FDA boost with priority review and more... |
| 2022-12-07 12:15 | | On its annual list of price hike offenders, ICER calls out Bausch's Xifaxan, J&J's Invega and more... |
| 2022-12-07 00:15 | | Lilly gearing up for 'substantial expansion' of diabetes med manufacturing by 2025 and more... |
| 2022-12-06 12:15 | | EpiPen litigation comes back to haunt Teva a decade after initial settlements and more... |
| 2022-12-06 00:15 | | Pfizer applies for FDA authorization for Omicron-retooled vaccine booster in kids under 5 and more... |
| 2022-12-05 12:15 | | In free fall, Clovis defaults on loan and agrees to further restrict Rubraca use and more... |
| 2022-12-05 00:15 | | This Week at FDA: FDA approves first FMT product, upcoming mpox guidance, and more and more... |
| 2022-12-02 12:15 | | 10 Massachusetts Biopharma Companies Hiring Now and more... |
| 2022-12-02 00:15 | | Regeneron's Libtayo posts lung cancer win with Bristol's Yervoy. But company won't seek approval and more... |
| 2022-12-01 12:15 | | Alex Gorsky to step down as J&J chair in 2023 and more... |
| 2022-12-01 00:15 | | Lilly's Covid-19 mAb no longer authorized due to Omicron subvariants, FDA says and more... |
